HCM
ESPR

Highbridge Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Highbridge Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-254,265
Closed -$674K – 303
2025
Q3 		$674K Hold
254,265
– – 0.03% 113
2025
Q2 		$250K Hold
254,265
– – 0.01% 141
2025
Q1 		$366K Hold
254,265
– – 0.01% 104
2024
Q4 		$559K Hold
254,265
– – 0.02% 136
2024
Q3 		$420K Hold
254,265
– – 0.01% 137
2024
Q2 		$564K Buy
+254,265
New +$598K 0.02% 112
2024
Q1 		– Sell
-221,722
Closed -$663K – 347
2023
Q4 		$663K Sell
221,722
-32,543
-13% -$42.2K 0.03% 116
2023
Q3 		$249K Hold
254,265
– – 0.01% 167
2023
Q2 		$353K Hold
254,265
– – 0.02% 153
2023
Q1 		$404K Hold
254,265
– – 0.01% 172
2022
Q4 		$1.58M Sell
254,265
-165,653
-39% -$1.18M 0.04% 224
2022
Q3 		$2.81M Hold
419,918
– – 0.04% 303
2022
Q2 		$2.67M Hold
419,918
– – 0.06% 311
2022
Q1 		$1.95M Buy
419,918
+74,323
+22% +$319K 0.05% 309
2021
Q4 		$1.73M Buy
+345,595
New +$2.77M 0.04% 314
2017
Q2 		– Sell
-31,064
Closed -$1.1M – 1344
2017
Q1 		$1.1M Buy
+31,064
New +$711K 0.02% 589
2016
Q4 		– Sell
-11,976
Closed -$165K – 1340
2016
Q3 		$165K Buy
+11,976
New +$136K ﹤0.01% 1211
2015
Q4 		– Sell
-236,669
Closed -$5.58M – 1564
2015
Q3 		$5.58M Buy
+236,669
New +$14.9M 0.09% 281
2015
Q2 		– Sell
-94,527
Closed -$8.75M – 1477
2015
Q1 		$8.75M Buy
+94,527
New +$6.1M 0.12% 222

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Highbridge Capital Management's ESPR Position: Q4 2025 in Review

Highbridge Capital Management sold out of Esperion Therapeutics (ESPR) in Q4 2025, closing a stake of 254,265 shares — an estimated $674K sold.

Highbridge Capital Management first reported a position in ESPR in Q1 2015 and held it in 19 quarters. The position peaked at $8.75M in Q1 2015. 200 funds tracked by Wall St. Rank hold ESPR as of Q4 2025.

  • Highbridge Capital Management reported no remaining Esperion Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Highbridge Capital Management sold 254,265 Esperion Therapeutics shares in Q4 2025, an estimated $674K.
  • Highbridge Capital Management first reported a position in Esperion Therapeutics in Q1 2015 and held it in 19 quarters.
  • Highbridge Capital Management's Esperion Therapeutics position peaked at $8.75M in Q1 2015.
  • 200 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2025.

Based on Highbridge Capital Management's 13F filing for Q4 2025, filed 11 Feb 2026.